Connor Clark & Lunn Investment Management Ltd. Has $1.12 Million Stock Position in STAAR Surgical (NASDAQ:STAA)

Connor Clark & Lunn Investment Management Ltd. increased its position in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 323.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 30,014 shares of the medical instruments supplier's stock after buying an additional 22,925 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.06% of STAAR Surgical worth $1,115,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of STAA. Mutual of America Capital Management LLC raised its holdings in STAAR Surgical by 214.7% during the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier's stock worth $1,260,000 after acquiring an additional 18,051 shares in the last quarter. Algert Global LLC increased its holdings in STAAR Surgical by 13.5% during the second quarter. Algert Global LLC now owns 116,655 shares of the medical instruments supplier's stock worth $5,554,000 after buying an additional 13,901 shares during the last quarter. ClariVest Asset Management LLC acquired a new stake in STAAR Surgical in the second quarter valued at $1,223,000. Granite Investment Partners LLC bought a new position in shares of STAAR Surgical in the 2nd quarter valued at about $17,237,000. Finally, Cetera Investment Advisers acquired a new position in shares of STAAR Surgical during the 2nd quarter worth about $1,135,000. Institutional investors and hedge funds own 96.70% of the company's stock.

STAAR Surgical Stock Performance

NASDAQ:STAA traded up $0.12 during mid-day trading on Thursday, hitting $28.18. 422,799 shares of the stock were exchanged, compared to its average volume of 709,411. The firm's 50-day simple moving average is $30.68 and its 200 day simple moving average is $36.32. STAAR Surgical has a fifty-two week low of $25.88 and a fifty-two week high of $52.68. The stock has a market capitalization of $1.39 billion, a price-to-earnings ratio of 64.05 and a beta of 0.61.

Analyst Upgrades and Downgrades

STAA has been the subject of several recent analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of STAAR Surgical in a research note on Thursday, October 31st. Stifel Nicolaus reduced their target price on STAAR Surgical from $50.00 to $44.00 and set a "buy" rating for the company in a research note on Monday, August 26th. Finally, Canaccord Genuity Group dropped their price target on STAAR Surgical from $41.00 to $31.00 and set a "hold" rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $43.33.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.